20
ASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia Date: September 21, 2018

ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

  • Upload
    others

  • View
    4

  • Download
    0

Embed Size (px)

Citation preview

Page 1: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

ASCO Quality Training Program

Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward.

Daniel Reed, MDUniversity of VirginiaDate: September 21, 2018

Page 2: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Institutional Overview

• 612-bed tertiary academic medical center in Charlottesville, VA• Inpatient

hematology/oncology unit: 35 beds

• UVA Cancer Center• NCI-designated cancer center

Presenter
Presentation Notes
Include basic demographic information about your practice/ institution. E.g. location, patient volume, practice setting (community, academic), # of oncologists, etc.
Page 3: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Daniel Reed, MD Team LeaderHannah Samley, RN Core Team MemberEric Pierce, MD Core Team MemberJeremy Sen, PharmD Other Team MemberHolly Mellot, RN Other Team MemberCamilo Fadul, MD Other Team MemberMichael Keng, MD QTP Coach

Team Members

Presenter
Presentation Notes
Team Leader: physician member that leads the team and is responsible for project deliverables. Team Members: have “fundamental knowledge” of the process you are addressing (e.g. frontline workers). Be sure to specify the role/discipline for each member. Project Sponsors: accountable for your overall effort, provides your team with direction and support, assists you with implementation when appropriate, and ensures that key stakeholders have appropriate involvement. Patient/ Family Members: provides the ‘voice of the customer’ and unique perspective. Ideal is if they have experienced the problem being addressed by the improvement project
Page 4: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

All patients who receive high dose methotrexate at the University of Virginia from 5/2017-5/2018 experienced a median 8 hour delay resulting in increased length of stay, increased cost of care, and decreased patient satisfaction.

Problem Statement

Presenter
Presentation Notes
Describes the concern or opportunity objectively. Describes the extent of the problem. Describes the impact of the problem Example: Readmissions are costly, associated with decreased quality, and are a target for non-payment by Medicare The current CHF readmission rate is 18% and a substantial portion of these readmissions are avoidable
Page 5: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Current State Process Map

Presenter
Presentation Notes
Purpose: to visually display the various steps, events, and operations that constitute a process.
Page 6: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Cause & Effect Diagram

Delay in MTX

Patient Physician

Pharmacy Clinic

Not meeting parameters

Late for appointment

Nursing

Delay in signing orders

Behind in clinic

Check in

Review of con meds

Delay in release of MTX

Lab orders

Scheduling

No standard way of calculating average urine output

No standard time set for notifying LIP when pre treatment parameters not met

Delay in starting chemotherapy due to high patient volume/acuity

Not following re admission instructions

Delay in making chemo

Waiting room

Presenter
Presentation Notes
Purpose: To broaden your thinking about the possible reasons for a problem. To develop ideas about the causes of a situation; some ideas will not prove to be correct. At this stage, your objective is to capture ideas. During the your 1:1 session you do not need to walk through each item on the cause & effect diagram. Instead discuss how you came up with the items to include on the cause & effect diagram, key lessons learned from the process, and how you identified the area to focus on.
Page 7: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Ideal State Process Map

Presenter
Presentation Notes
Purpose: To broaden your thinking about the possible reasons for a problem. To develop ideas about the causes of a situation; some ideas will not prove to be correct. At this stage, your objective is to capture ideas. During the your 1:1 session you do not need to walk through each item on the cause & effect diagram. Instead discuss how you came up with the items to include on the cause & effect diagram, key lessons learned from the process, and how you identified the area to focus on.
Page 8: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

• Measures: • Process measure: Time to HD MTX administration, time to urine output,

time to urine pH >7.0• Outcome Measure: Length of Stay (lagging indicator)

• Patient population: Patients receiving systemic high dose methotrexate• Excluded: Neuro oncology patients

• Calculation methodology• Numerator: number of times a delay occurred• Denominator: total number of delays

• Data source: EPIC chart review

• Data collection frequency: One Year

• Data quality(any limitations): Retrospective collection of data, sample bias

Measures

Presenter
Presentation Notes
Describe your outcome, process or balance measures which you will present as your baseline data and change data. Measures should be directly related to your aim statement. If you have more than one measure you will want to create a slide for each measure. Describe the measure and note whether it is your outcome, process or balance measure. Include the patient population (who is included and any exclusions). Specify the calculation methodology (specify the numerator, denominator if applicable). Describe the data source, data collection frequency, quality of data (any limitations). Can also add a slide to show off your data collection tools that you developed.
Page 9: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Baseline Data

• 157 total charts reviewed from 5/2017-5/2018 61 neuro oncology patients

excluded 86 hematology/oncology

patients examined• Median time to high dose

methotrexate: 8 h• Median time to urine ouput >125

cc/hr: 9.13 • Median time to pH >7.0 : 6.94

Presenter
Presentation Notes
Links directly to the measurement implied in your primary aim statement.
Page 10: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Baseline DataChemotherapy Regimen

# of Patients Median Time to

Methotrexate

Median Time to

pH 7

Median time to

UOP >125 cc/hr

Median Length of

Stay

12 g/m2 12 8.25 19.42 20.3 4.03

3.5 g/m2 50 9.73 6.87 11.02 4.04

6 g/m2 1 14.90 4.72 14.9 4.22

8 g/m2 1 7.53 4.28 8.85 3.07

COG AALL0034

14 8.80 6.03 7.84 4.03

HyperCVAD 17 8.87 9.30 6.12 4.06

SMILE 1 20.9 211.8 14.7 15

Presenter
Presentation Notes
Defines the team’s specific improvement objective – what you are trying to accomplish. Aim statements should be SMART - specific, measurable, attainable, relevant and time bound. Example: By June 30, 2011, increase the accuracy of medication lists one week after physical exams and chronic disease visits to 90% by providing physicians with accurate patient generated medication lists during the targeted visit at XYZ clinic.
Page 11: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Diagnostic Data: Tally ChartReason For Delay Frequency

Urine output parameter not met 42

Urine pH parameter not met 24

Lack of standard process 16

Labs not ordered 10

Delay in release of MTX 4

Total 96

Presenter
Presentation Notes
Any observations, tally sheet data, interviews, that helped you understand your process, prioritize opportunities, etc. Displayed in a Pareto chart, frequency distribution, run chart, etc. (demonstrates how you identified your opportunities for improvement and how you prioritized your specific area of focus that will relate to your aim statement. Quantify which branch of your cause and effect diagram is contributing most to your problem. Data collected should help inform your aim statement – provides a data driven decision and helps support why you are focusing on your specific project. Be sure to indicate where the data came from (i.e. survey, chart review, etc). If you include survey data, identify the population surveyed, the number of participants included in the survey request and the number of responses to each question.
Page 12: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Diagnostic Data: Pareto Chart

0.00%

10.00%

20.00%

30.00%

40.00%

50.00%

60.00%

70.00%

80.00%

90.00%

100.00%

0

5

10

15

20

25

30

35

40

45

Urine outputparameter not met

Urine ph parameternot met

Lack ofstandardization

Labs not ordered Pharmacy dealyrelease

Presenter
Presentation Notes
Links directly to the measurement implied in your primary aim statement.
Page 13: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

By January 2019, leukemia and lymphoma patients receiving high dose methotrexate inpatient will have a 25% reduction in treatment start time from baseline

Aim Statement

Presenter
Presentation Notes
Defines the team’s specific improvement objective – what you are trying to accomplish. Aim statements should be SMART - specific, measurable, attainable, relevant and time bound. Example: By June 30, 2011, increase the accuracy of medication lists one week after physical exams and chronic disease visits to 90% by providing physicians with accurate patient generated medication lists during the targeted visit at XYZ clinic.
Page 14: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Prioritized List of Changes (Priority/Pay –Off Matrix)

Encourage oral hydration prior to admission

Give Methotrexate Outpatient

UA in outpatient clinic before patient is admitted

Nurses standardizing urine outputNursing standardizing urine pH method

High

Impa

ct

Low

Easy Difficult

Ease of Implementation

Prescribing oral alkalization prior to admission

Page 15: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

PDSA Plan (Test of Change)Date of PDSA

CycleDescription of Intervention

Results Action Steps

11/1/2018 Oral and IV prehydration

Ongoing

Page 16: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

PDSA Cycle

- All patients provided education regarding prehydration with 64 fluid ounces of fluid day prior to admission

- Patients seen in clinic on day of admission and sent to infusion for 1 liter bolus for prehydration

- Select patients provided prescriptions for oral bicarbonate and acetazolamide

Page 17: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Change Data

Mean

UCL 3σ

LCL 3σ

-10.00

-5.00

0.00

5.00

10.00

15.00

20.00

25.00

30.00

35.00

1 3 5 7 9 1113151719212325272931333537394143454749515355575961636567697173757779818385878991

3 Process Control Chart Time to Methotexate

PDSA Cycle 1: oral alkalization

PDSA Cycle 2: PrehydrationResolution

Page 18: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Problems Encountered

• Patient factors: compliance; education from nursing staff

•Unit acuity/time

•Lack of standardization among nursing staff

Page 19: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Conclusions

• Too early to examine PDSA Cycle • Education opportunity for nursing and clinical staff• Goal is to decrease time to methotrexate to hopefully decrease length of stay and improve patient experience

Page 20: ASCO’s Quality Training ProgramASCO Quality Training Program Reducing Time to High Dose Methotrexate Administration on an Inpatient Oncology Ward. Daniel Reed, MD University of Virginia

Next Steps/Plan for Sustainability

• Monthly meetings with Nurse coordinators to ensure compliance with pre hydration protocol• Weekly collection of data for MTX patients admitted